Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at ther...
Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads
About this item
Full title
Author / Creator
Publisher
London, England: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
London, England: SAGE Publications
Subjects
More information
Scope and Contents
Contents
Objective:
The objective of this paper is to estimate the risk of reaching well-established disability milestones after withdrawal of natalizumab (NTZ) due to concern about the risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis (MS).
Methods:
Data from 415 patients with MS followed-up for six years after...
Alternative Titles
Full title
Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1728669728
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1728669728
Other Identifiers
ISSN
1352-4585
E-ISSN
1477-0970
DOI
10.1177/1352458515570768
